πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10400025

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10377751

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10369142

Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10370449

Methods for treating skin infection by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10358433

Diamide compounds having muscarinic receptor antagonist and Ξ²2 adrenergic receptor agonist

Theravance Respiratory Company, LLC Β· Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10343995

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10336769

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. Β· Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10329343

Methods for treating headache using antagonist antibodies directed against calcitonin gene

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10322161

EPHA4 cyclic peptide antagonists for neuroprotection and neural repair

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10316073

FCRN antagonists and methods of use

The Board of Regents of the University of Texas System Β· Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10314904

Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10301371

Cyclic monomer and dimer peptides having integrin antagonist activity

Protagonist Therapeutics, Inc. Β· Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10300074

Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10300072

Cyclohexylamine derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist acti

Almirall, S.A. Β· Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10258582

Nicotinic receptor non-competitive antagonists

Catalyst Biosciences, Inc. Β· Granted Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10238659

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagoni

Corcept Therapeutics Incorporated Β· Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10239870

Dopamine D3 receptor antagonists

Indivior UK Limited Β· Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10137193

Methods for treating or preventing asthma by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10130681

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10125145

5-HT3 receptor antagonists

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10105366

Selective calcium channel antagonists

Northwestern University Β· Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10105316

Inhalation compositions comprising muscarinic receptor antagonist

ARVEN ILAC SANAYI VE TICARET A.S. Β· Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10106616

Antagonist antibodies to human prolactin receptor (PRLR)

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10106503

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted